RELAPSED/REFRACTORY MULTIPLE MYELOMA

This early-stage study tests an experimental drug called etentamig combined with standard treatments for people with multiple myeloma that has returned or stopped responding to therapy. The main goals are to find the safest dose and check for side effects. About 320 adults will t…

This study tests whether adding a drug called cevostamab after standard CAR T cell therapy can help people with relapsed or refractory multiple myeloma achieve a deeper remission. About 30 adults who have already received CAR T cells will get cevostamab infusions every 3 weeks fo…

This early-phase study tests a combination of two types of immune-boosting antibodies (talquetamab or teclistamab plus a PD-1 inhibitor) in 74 people with multiple myeloma that has returned or stopped responding to prior treatments. The main goal is to find safe doses and underst…

This study tests a new way to give the drug isatuximab (as a shot under the skin) along with two other medicines (carfilzomib and dexamethasone) to adults whose multiple myeloma has come back or stopped responding to treatment. About 118 people who have had 1 to 3 prior treatment…

This study tracks 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to watch for long-term side effects and safety issues over 15 years. No new treatment is given—just regular check-ups to see how patients are doing.…